Kyverna Therapeutics, Inc. (Ticker: KYTX), based in Emeryville, California, is set for its IPO on the NASDAQ exchange, aiming to list on February 8, 2024. This clinical-stage biopharmaceutical company is dedicated to developing cell therapies for patients with autoimmune diseases, focusing initially on lupus nephritis (LN) and systemic sclerosis (SSc). Kyverna Therapeutics plans to offer 11.12 million shares, with a price range of $17.00 to $19.00, seeking to raise approximately $200.16 million. The offering is managed by by J.P. Morgan, Morgan Stanley, Leerink Partners, and Wells Fargo Securities.

The company's leading product candidate, KYV-101, is an autologous CD19 CAR T-cell therapy, showing promise in early clinical trials for its potential to modify diseases by depleting B cells, which contribute to autoimmune diseases. In partnership with Intellia Therapeutics, Inc., Kyverna is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate, expanding their approach to include off-the-shelf cell therapy options.